Tumoral high-endothelial venule (TU-HEV) formation after antiangiogenic immunotherapy generates niches for progenitor T-cell expansion and differentiation into effector T cells.

©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.